Using this assay, we demonstrated that TOP1 protein levels are decreased in both HCT116 flank tumor tissue and bone marrow following unconjugated exatecan administration, while CBX-12 selectively depletes TOP1 in the tumor, with no effect in the bone marrow (Figure 2C). This evidence concerns the gene TOP1 and neoplasm.